Efficacy and safety of a triple combination of atezolizumab ...
The triple combination of atezolizumab, bevacizumab, and GEMOX shows promise for advanced biliary tract cancer (BTC) patients, with a 76.7% ORR and 90.0% DCR. ALS2CL mutations may predict therapy efficacy. Common TRAEs include fever and neutropenia. This regimen offers a potential new treatment avenue for advanced BTC.
Reference News
Efficacy and safety of a triple combination of atezolizumab ...
The triple combination of atezolizumab, bevacizumab, and GEMOX shows promise for advanced biliary tract cancer (BTC) patients, with a 76.7% ORR and 90.0% DCR. ALS2CL mutations may predict therapy efficacy. Common TRAEs include fever and neutropenia. This regimen offers a potential new treatment avenue for advanced BTC.